Sentinel Pension Advisors Inc. Invests $231,000 in AbbVie Inc. (NYSE:ABBV)

Sentinel Pension Advisors Inc. bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,168 shares of the company’s stock, valued at approximately $231,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in AbbVie by 128.5% during the fourth quarter. Wellington Management Group LLP now owns 954,374 shares of the company’s stock worth $147,899,000 after buying an additional 536,730 shares during the last quarter. Foster Group Inc. lifted its stake in shares of AbbVie by 7.2% in the 1st quarter. Foster Group Inc. now owns 8,182 shares of the company’s stock valued at $1,490,000 after purchasing an additional 547 shares during the last quarter. New Hampshire Trust lifted its stake in shares of AbbVie by 3.1% in the 1st quarter. New Hampshire Trust now owns 36,357 shares of the company’s stock valued at $6,621,000 after purchasing an additional 1,092 shares during the last quarter. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 1.6% in the 1st quarter. Ellenbecker Investment Group now owns 5,979 shares of the company’s stock valued at $1,089,000 after purchasing an additional 95 shares during the last quarter. Finally, Safeguard Financial LLC purchased a new stake in shares of AbbVie in the 1st quarter valued at $235,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total value of $12,403,580.00. Following the completion of the transaction, the chairman now directly owns 446,599 shares in the company, valued at approximately $83,299,645.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.25% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $190.46 on Thursday. The stock has a fifty day moving average price of $194.50 and a 200 day moving average price of $177.63. The stock has a market cap of $336.33 billion, a PE ratio of 56.52, a P/E/G ratio of 2.66 and a beta of 0.63. AbbVie Inc. has a 1 year low of $135.85 and a 1 year high of $199.95. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08. AbbVie had a return on equity of 203.66% and a net margin of 9.71%. The firm had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.02 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. AbbVie’s revenue was up 4.3% on a year-over-year basis. Sell-side analysts forecast that AbbVie Inc. will post 10.85 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be issued a $1.55 dividend. The ex-dividend date is Tuesday, October 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.26%. AbbVie’s dividend payout ratio (DPR) is 183.98%.

Wall Street Analyst Weigh In

ABBV has been the topic of several research analyst reports. Truist Financial boosted their price objective on AbbVie from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 10th. UBS Group upped their price target on AbbVie from $185.00 to $195.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. BMO Capital Markets upped their price target on AbbVie from $180.00 to $214.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Piper Sandler Companies reiterated an “overweight” rating and issued a $190.00 price objective on shares of AbbVie in a report on Wednesday, July 3rd. Finally, Piper Sandler increased their price objective on AbbVie from $196.00 to $209.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $198.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.